CQS Cayman’s Juno Therapeutics, Inc. JUNO Stock Holding History

CQS Cayman’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-52,000	Closed	-$2.29M	–	143
2015 Q4	$2.29M	Buy	+52,000	New	+$2.58M	0.16%	90
2015 Q3	–	Sell	-25,000	Closed	-$1.33M	–	209
2015 Q2	$1.33M	Buy	+25,000	New	+$1.33M	0.08%	125

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

CQS Cayman's JUNO Position: Q1 2016 in Review

CQS Cayman sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2016, closing a stake of 52,000 shares — an estimated $2.29M sold.

CQS Cayman first reported a position in JUNO in Q2 2015 and held it in 2 quarters. The position peaked at $2.29M in Q4 2015. 158 funds tracked by Wall St. Rank hold JUNO as of Q1 2016.

CQS Cayman reported no remaining Juno Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
CQS Cayman sold 52,000 Juno Therapeutics, Inc. shares in Q1 2016, an estimated $2.29M.
CQS Cayman first reported a position in Juno Therapeutics, Inc. in Q2 2015 and held it in 2 quarters.
CQS Cayman's Juno Therapeutics, Inc. position peaked at $2.29M in Q4 2015.
158 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2016.

Based on CQS Cayman's 13F filing for Q1 2016, filed 4 May 2016.